• 2024 AAM Generic & Biosimilar Medicines Savings Report
    NEW: 2024 U.S. Generic & Biosimilar Medicines Savings Report
    Generic and biosimilar medicines saved $445 billion in 2023. Representing 90 percent of prescriptions filled but only 13 percent of spending, generics and biosimilars are an integral part of the U.S. healthcare system. However, the sustainability of this industry remains fragile.
  • Dr. Janet Woodcock is speaking at GRx+Biosims 2024
    Dr. Janet Woodcock is speaking at GRx+Biosims 2024
    Join us in celebrating Dr. Janet Woodcock’s remarkable 38-year career at the U.S. FDA. As a trailblazer in drug regulation, she has shaped the pharmaceutical landscape and left an enduring legacy. Presented by Women in Health Policy (WiHP) and powered by AAM, this special session will explore her visionary leadership and achievements.
  • GRx+Biosims 2024
    Exploring the Future of Generics and Biosimilars at GRx+Biosims 2024
    Join us Oct 21–23 in Rockville, MD for the leading scientific, regulatory, and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from FDA experts, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development. Sign up before Sep 20 for early bird discount.
    Watch Video
  • Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
    Avalere analysis finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers.
  • Hatch-Waxman Turns 40
    AAM White Paper: Hatch-Waxman Turns 40
    “Since the introduction of this law, we have all seen incredible savings. But even as we celebrate the success of forty years of Hatch-Waxman, those savings, the increased patient access, and a model of generic adoption that leads the world, are at risk.” —David Gaugh, Interim President & CEO, AAM.

Our Brands and Campaigns

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.